Atlas Trials

ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

Clinical trial NCT07448610 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07448610
Sponsor
Novartis Pharmaceuticals
Status
NOT_YET_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Spinal Muscular Atrophy
Start date
2026-07-01
Primary completion
2032-05-03
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.